can you create a template for a consultation to renew psychostimulant

Consultation Template for Renewing Psychostimulant Medication in Adult ADHD

• Patient Identity and Diagnosis Confirmation: Confirm the patient’s identity and review that the diagnosis of ADHD still holds based on DSM or ICD criteria, including a documented history of childhood ADHD and current moderate to severe functional impairment in at least two settings (e.g. social, academic, occupational) SmPC Meflynate,SmPC Meflynate,SmPC Affenid,SmPC Metyrol,NICE NG87.
• Medication Review: Document current psychostimulant medication name, dose, formulation (e.g. modified-release), adherence, and any recent dose changes or titration NICE NG87,NICE CKS.
• Effectiveness Assessment: Assess clinically how well the medication is controlling ADHD symptoms throughout the day, including restlessness, inattentiveness, and impulsivity, and ask the patient about perceived benefits and impact on employment and social functioning NICE NG87.
• Adverse Effects Monitoring: Query and document any side effects, encouraging the patient to use adverse effect checklists if available; assess cardiovascular symptoms and measure pulse and blood pressure with an appropriately sized cuff to detect any concerns NICE NG87.
• Physical Health Review: Review medical history for contraindications or new health conditions, measure and document weight (every 6 months for adults) to monitor for medication-related changes, and incorporate any relevant cardiovascular assessments if new symptoms appear NICE NG87.
• Risk Assessment: Reassess risk of substance misuse, diversion, or misuse of stimulants, being cautious if such risks have emerged or changed NICE NG87.
• Coexisting Conditions: Evaluate mental health and neurodevelopmental conditions that may affect treatment or require dose adjustments (e.g. anxiety, bipolar disorder) NICE NG87.
• Shared Care Confirmation: Confirm shared care arrangements are in place with specialist services overseeing ADHD treatment initiation and dose optimization, with monitoring responsibilities delegated appropriately NICE NG87,NICE CKS.
• Adherence Support: Discuss non-pharmacological treatments and adherence issues including any barriers the patient experiences and strategies to support ongoing treatment engagement NICE NG87.
• Medication Continuation Decision: Discuss with the patient preferences and review the balance of benefits and harms; document reasons if continuing medication, or consider a trial of dose reduction or discontinuation if clinically appropriate NICE NG87.
• Prescription Issuance: Issue prescription in compliance with controlled drugs legislation and local shared care protocols only after thorough review NICE NG87.
• Plan Next Review: Schedule at least annual medication review to include comprehensive reassessment of symptoms, adverse effects, and treatment need NICE NG87.